TSS
NAVB

Two Sigma Securities’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Two Sigma Securities’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-31,553
Closed -$2.83K – 3819
2023
Q3 		$2.83K Sell
31,553
-27,756
-47% -$2.58K ﹤0.01% 2816
2023
Q2 		$5.46K Buy
59,309
+39,984
+207% +$6.37K ﹤0.01% 2662
2023
Q1 		$5.03K Sell
19,325
-1,820
-9% -$531 ﹤0.01% 2527
2022
Q4 		$4.44K Buy
+21,145
New +$5.29K ﹤0.01% 2464
2022
Q3 		– Sell
-13,510
Closed -$10K – 3316
2022
Q2 		$10K Buy
+13,510
New +$11.5K ﹤0.01% 2063
2019
Q1 		– Sell
-3,190
Closed -$7K – 2675
2018
Q4 		$7K Buy
+3,190
New +$13.1K ﹤0.01% 2044
2018
Q1 		– Sell
-701
Closed -$5K – 3102
2017
Q4 		$5K Sell
701
-487
-41% -$4.12K ﹤0.01% 1695
2017
Q3 		$10K Buy
+1,188
New +$10.1K ﹤0.01% 869
2017
Q1 		– Sell
-1,341
Closed -$17K – 1208
2016
Q4 		$17K Sell
1,341
-613
-31% -$9.72K 0.01% 662
2016
Q3 		$36K Buy
+1,954
New +$24.7K 0.01% 577
2016
Q1 		– Sell
-752
Closed -$20K – 443
2015
Q4 		$20K Buy
+752
New +$26.1K 0.02% 206

Other funds holding NAVB

BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.28B AUM 38.1% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

Two Sigma Securities's NAVB Position: Q4 2023 in Review

Two Sigma Securities sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2023, closing a stake of 31,553 shares — an estimated $2.83K sold.

Two Sigma Securities first reported a position in NAVB in Q4 2015 and held it in 11 quarters. The position peaked at $36K in Q3 2016. 4 funds tracked by Wall St. Rank hold NAVB as of Q4 2023.

  • Two Sigma Securities reported no remaining Navidea Biopharmaceuticals Inc. position as of Q4 2023 after selling out during the quarter.
  • Two Sigma Securities sold 31,553 Navidea Biopharmaceuticals Inc. shares in Q4 2023, an estimated $2.83K.
  • Two Sigma Securities first reported a position in Navidea Biopharmaceuticals Inc. in Q4 2015 and held it in 11 quarters.
  • Two Sigma Securities's Navidea Biopharmaceuticals Inc. position peaked at $36K in Q3 2016.
  • 4 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2023.

Based on Two Sigma Securities's 13F filing for Q4 2023, filed 14 Feb 2024.